317 related articles for article (PubMed ID: 33461918)
21. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
Bansal N; Raturi M; Bansal Y
Transfus Clin Biol; 2021 Aug; 28(3):308-309. PubMed ID: 33971319
[TBL] [Abstract][Full Text] [Related]
22. Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout.
Rubin EJ; Baden LR; Lee TH; Morrissey S
N Engl J Med; 2021 Jan; 384(1):e13. PubMed ID: 33406335
[No Abstract] [Full Text] [Related]
23. Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.
Farag YMK
Mayo Clin Proc; 2020 Dec; 95(12):2801-2802. PubMed ID: 33276848
[No Abstract] [Full Text] [Related]
24. Current Scenario and Future Prospect in the Management of COVID-19.
Borah P; Deb PK; Deka S; Venugopala KN; Singh V; Mailavaram RP; Kalia K; Tekade RK
Curr Med Chem; 2021; 28(2):284-307. PubMed ID: 32900341
[TBL] [Abstract][Full Text] [Related]
25. Convalescent plasma, political narrative, and public health ethics in the Covid-19 pandemic.
Agrawal S; Agarwal A; Jain Y
Indian J Med Ethics; 2021; VI(3):1-7. PubMed ID: 34287194
[TBL] [Abstract][Full Text] [Related]
26. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
27. COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified.
Ferrara F; Pianesi L; Vitiello A
Immunol Res; 2021 Apr; 69(2):115-116. PubMed ID: 33860404
[No Abstract] [Full Text] [Related]
28. In Reply - Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.
Joyner MJ; Senefeld JW; Klassen SA; Fairweather D; Wright RS; Carter RE
Mayo Clin Proc; 2020 Dec; 95(12):2802-2803. PubMed ID: 33276849
[No Abstract] [Full Text] [Related]
29. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
Pau AK; Aberg J; Baker J; Belperio PS; Coopersmith C; Crew P; Grund B; Gulick RM; Harrison C; Kim A; Lane HC; Masur H; Sheikh V; Singh K; Yazdany J; Tebas P;
Ann Intern Med; 2021 Jan; 174(1):93-95. PubMed ID: 32976026
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
[No Abstract] [Full Text] [Related]
31. COVID-19: benefits and risks of passive immunotherapeutics.
Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management.
Ochani R; Asad A; Yasmin F; Shaikh S; Khalid H; Batra S; Sohail MR; Mahmood SF; Ochani R; Hussham Arshad M; Kumar A; Surani S
Infez Med; 2021 Mar; 29(1):20-36. PubMed ID: 33664170
[TBL] [Abstract][Full Text] [Related]
33. Convalescent Plasma Therapy against COVID-19: An Update on the Changing Facets of the ongoing Pandemic.
Abullais SS; Arora S; Wahab S; Grover V; Alshahrani MY; Shamsudeen SM; Mohammed Asif S; Faragalla AI; Elagib MF
Curr Pharm Biotechnol; 2023; 24(12):1515-1523. PubMed ID: 36733203
[TBL] [Abstract][Full Text] [Related]
34. Convalescent plasma and COVID-19: Time for a second-second look?
Joyner MJ; Carter RE; Fairweather D; Wright RS
Transfus Med; 2023 Feb; 33(1):16-20. PubMed ID: 36089562
[TBL] [Abstract][Full Text] [Related]
35. Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy.
Fisher DL; Pavel A; Malnick S
QJM; 2021 Aug; 114(5):319-320. PubMed ID: 33416888
[No Abstract] [Full Text] [Related]
36. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
[No Abstract] [Full Text] [Related]
37. The Assessment of Convalescent Plasma Efficacy against COVID-19.
Casadevall A; Grossman BJ; Henderson JP; Joyner MJ; Shoham S; Pirofski LA; Paneth N
Med; 2020 Dec; 1(1):66-77. PubMed ID: 33363284
[TBL] [Abstract][Full Text] [Related]
38. "A Most Equitable Drug": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development.
Grundy Q; Campbell C; Ali R; Herder M; Holloway K
J Law Med Ethics; 2024; 52(1):80-97. PubMed ID: 38818600
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.
Taşlı NP; Gönen ZB; Kırbaş OK; Gökdemir NS; Bozkurt BT; Bayrakcı B; Sağraç D; Taşkan E; Demir S; Ekimci Gürcan N; Bayındır Bilgiç M; Bayrak ÖF; Yetişkin H; Kaplan B; Pavel STI; Dinç G; Serhatlı M; Çakırca G; Eken A; Aslan V; Yay M; Karakukcu M; Unal E; Gül F; Basaran KE; Ozkul Y; Şahin F; Jones OY; Tekin Ş; Özdarendeli A; Cetin M
Front Immunol; 2022; 13():824378. PubMed ID: 35401544
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency.
Li M; Lou F; Fan H
Signal Transduct Target Ther; 2021 Apr; 6(1):151. PubMed ID: 33839737
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
